New hope drug enters first human tests for Tough-to-Treat breast cancer

NCT ID NCT05339685

Ongoing Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

Summary

This is an early-stage study to test the safety and side effects of a new injectable drug called BL-M02D1 in adults with advanced triple-negative breast cancer or other solid tumors that have spread and have no standard treatment options. The main goals are to find the highest dose patients can tolerate without severe side effects and to see how the drug behaves in the body. Researchers will also look for early signs that the drug might help shrink tumors.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Hubei Cancer Hospital

Wuhan, Hubei, China
Renmin Hospital of Wuhan University

Wuhan, Hubei, China
Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine

Hangzhou, Zhejiang, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University

Guangzhou, Guangdong, 510120, China
The First Affiliated Hospital of Bengbu Medical College

Bengbu, Anhui, China
The First Affiliated Hospital of Jilin University

Changchun, Jilin, China
The Second Affiliated Hospital of Guilin Medical University

Guilin, Guangxi, China
Yueyang People's Hospital

Yueyang, Hunan, China
Zhongnan Hospital of Wuhan University

Wuhan, Hubei, China
Zhujiang Hospital of Southern Medical University

Guangzhou, Guangdong, China

Conditions

Explore the condition pages connected to this study.

BREAST CANCER